An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days

Trial Profile

An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Dec 2013

At a glance

  • Drugs Iloperidone (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 13 Mar 2013 Status changed from discontinued to completed as reported by Clinicaltrials.gov.
    • 31 Oct 2012 Status changed from recruiting to discontinued, as reported by Clinicaltrials.gov.
    • 25 Apr 2012 Planned end date changed from 1 Jul 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top